187 results
8-K
HGENQ
Humanigen, Inc
8 Jan 24
Entry into a Material Definitive Agreement
5:02pm
the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified
8-K
EX-2.1
HGENQ
Humanigen, Inc
8 Jan 24
Entry into a Material Definitive Agreement
5:02pm
the dispute; and (b) in the event of litigation regarding such dispute, the party prevailing in such litigation shall be entitled to receive from the non … -prevailing Party, costs and attorneys’ fees with respect to such litigation.
Article III
Representations and Warranties of Seller
Except as set
8-K
HGENQ
Humanigen, Inc
19 Apr 23
Other Events
6:00am
statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate
8-K
HGENQ
Humanigen, Inc
6 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:45pm
the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of historical fact
8-K
EX-99.1
wwx2xzg8gahofwk4o6
14 Nov 22
Humanigen Reports Third Quarter 2022 Financial Results
4:16pm
8-K
EX-99.1
ybsbwiumd7
12 Aug 22
Humanigen Reports Second Quarter 2022 Financial Results
4:07pm
8-K
EX-99.1
hevofyz
26 Jul 22
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones
4:05pm
8-K
EX-99.1
xocsbp
13 Jul 22
Humanigen receives preliminary topline data from NIH/NIAID study of lenzilumab in ACTIV-5/BET-B
6:01am
8-K
rkn76qi52jx30
30 Jun 22
Other Events
8:24am
8-K
EX-99.1
o148ud4
5 May 22
Humanigen Reports First Quarter 2022 Financial Results
4:05pm
424B5
upoibk9y2 rf
14 Apr 22
Prospectus supplement for primary offering
5:27pm
8-K
EX-99.1
1q3y7h z6n
12 Apr 22
Regulation FD Disclosure
9:00am